News
Three releases, one year
-
9 May 2016
ProteoThera, Inc. Receives Allowance for a Broad U.S. Patent Covering Matrix-Binding Technology Platform
NEWTON, Massachusetts – May 9, 2016 – ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced that it has received a notice of allowance for a broad U.S. patent covering its matrix-binding technology platform.
-
8 January 2016
Targeted Drug-Delivery Company ProteoThera, Inc. To Present At BioTech Showcase™ Monday, Jan. 11 at 11:30 am PT
NEWTON, Massachusetts – January 8, 2016 – ProteoThera, Inc. announced that its Chief Executive Officer, Patrick O’Donnell, would present the Company’s targeted drug-delivery platform technology, internal product development strategy and research collaboration opportunities at the 8th annual BioTech Showcase conference. Dr. Parth Patwari, ProteoThera’s Chief Science Officer, was also in attendance.
-
2 December 2015
United States PTO Grants a Key Patent Supporting The ProteoThera Matrix-Binding Technology Platform
NEWTON, Massachusetts – December 2, 2015 – ProteoThera announced a notice of grant from the USPTO for a fundamental patent entitled “Methods of promoting cardiac repair using growth factors fused to heparin binding sequences”, U.S. patent number 9,187,517, to which ProteoThera holds exclusive worldwide rights through its existing agreement with Brigham and Women’s Hospital.
The patent behind the December 2015 release
U.S. patent 9,187,517, “Methods of promoting cardiac repair using growth factors fused to heparin binding sequences”, applied for on 7 November 2007 and licensed exclusively worldwide to ProteoThera through its agreement with Brigham and Women’s Hospital.